Condition: Ovarian Cancer · Sponsor: Boryung Pharmaceutical Co., Ltd
This was a multicenter, open-label, randomized, crossover bioequivalence study to evaluate the pharmacokinetics and safety of BR2022 and BR2022-1 in Patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer.
This description comes directly from the study's public registry record.
Shinyoung Oh · +82 2-708-8000 · syoh@boryung.co.kr
Always discuss trial participation with your own doctor first.
| Asan Medical Center | Seoul, Songpa District, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07069335